[
    [
        {
            "time": "",
            "original_text": "医药行业：把握行业新秩序下的龙头新趋势",
            "features": {
                "keywords": [
                    "医药",
                    "行业",
                    "龙头",
                    "趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业：把握行业新秩序下的龙头新趋势",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[买入评级]泰格医药(300347)：业绩符合预期 方达港股上市进程稳步推进",
            "features": {
                "keywords": [
                    "泰格医药",
                    "买入评级",
                    "业绩",
                    "方达",
                    "港股",
                    "上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]泰格医药(300347)：业绩符合预期 方达港股上市进程稳步推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中金医药月度7+5组合：7月组合",
            "features": {
                "keywords": [
                    "中金医药",
                    "月度组合",
                    "7+5",
                    "7月"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中金医药月度7+5组合：7月组合",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[增持评级]泰格医药(300347)半年度业绩预告点评：内生持续高增长 汇兑损益或缩窄",
            "features": {
                "keywords": [
                    "泰格医药",
                    "增持评级",
                    "半年度",
                    "业绩",
                    "内生增长",
                    "汇兑损益"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级]泰格医药(300347)半年度业绩预告点评：内生持续高增长 汇兑损益或缩窄",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]